Core Insights - CG Oncology, Inc. is set to present late-breaking clinical and translational data from the BOND-003 Cohort C at the 40th Annual European Association of Urology (EAU) Congress in Madrid, Spain, from March 21-24, 2025 [1] - The presentations will focus on cretostimogene grenadenorepvec, an investigational oncolytic immunotherapy for bladder cancer patients [4][5] Presentation Details - The updated clinical results for BOND-003 Cohort C will be presented by Dr. Trinity J. Bivalacqua on March 24, 2025, from 10:45 to 12:15 CET [2] - Additional presentations will include translational correlates using urinary genomic disease burden and ongoing trials related to cretostimogene grenadenorepvec [3] Product Information - Cretostimogene grenadenorepvec is being evaluated in multiple Phase 3 clinical trials for high-risk non-muscle invasive bladder cancer (NMIBC) and intermediate-risk NMIBC [4][5] - The investigational therapy is delivered intravesically and aims to provide a bladder-sparing treatment option for patients unresponsive to Bacillus Calmette Guerin (BCG) therapy [4] Company Overview - CG Oncology is a late-stage clinical biopharmaceutical company focused on developing innovative immunotherapies for bladder cancer, aiming to enhance the quality of life for patients [6]
CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates